Elan Corp. plc (ELN)
Furman Selz analyst Bruce Schackman reestablished coverage and added the stock to the Furman Selz Recommended List. He said ELN already has in place the strategic elements to be a successful drug delivery company in the late 1990s and to sustain annual EPS growth of 35-40 percent.